Galectin Therapeutics (GALT) Non Operating Income (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Non Operating Income of -$969000.0 for Q1 2026, up 44.12% year-over-year from -$672367.3 in Q1 2025, and up 54.61% quarter-over-quarter from -$2.1 million in Q4 2025.
Powered by 
Analysis
Galectin Therapeutics (GALT) Non Operating Income (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Non Operating Income history runs 17 years deep, the most recent figure standing at -$969000.0 for Q1 2026.
- In Q1 2026, Non Operating Income rose 44.12% year-over-year to -$969000.0; the TTM figure through Mar 2026 stood at -$10.0 million (down 121.57% YoY), while the FY2025 annual figure was -$10.8 million, down 133.01% from the prior year.
- Non Operating Income for Q1 2026 stood at -$969000.0, up from -$2.1 million in the prior quarter.
- The five-year high for Non Operating Income was $461000.0 in Q4 2024, with the low at -$4.0 million in Q3 2025.
- The 5-year median for Non Operating Income is -$1.1 million (2024), against an average of -$1.2 million.
- The sharpest annual moves came in 2023 and 2024: Non Operating Income tumbled 43500.0% in 2023, then surged 205.73% in 2024.
- Galectin Therapeutics' Non Operating Income stood at -$1000.0 in 2022, then sank by 43500.0% to -$436000.0 in 2023, then soared by 205.73% to $461000.0 in 2024, then sank by 563.12% to -$2.1 million in 2025, then soared by 54.61% to -$969000.0 in 2026.
- Business Quant data shows GALT's Non Operating Income at -$969000.0 in Q1 2026, -$2.1 million in Q4 2025, and -$4.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Galectin Therapeutics | 304.34 Mn | 304.34 Mn | - | -5.13 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5.13 Mn |
| Mar 31, 2026 | -969,000.00 |
| Dec 31, 2025 | -2.14 Mn |
| Sep 30, 2025 | -3.99 Mn |
| Jun 30, 2025 | -2.90 Mn |
| Mar 31, 2025 | -1.73 Mn |
| Dec 31, 2024 | 461,000.00 |
| Sep 30, 2024 | -2.15 Mn |
| Jun 30, 2024 | -1.08 Mn |
| Mar 31, 2024 | -1.84 Mn |
| Dec 31, 2023 | -436,000.00 |
| Sep 30, 2023 | -1.26 Mn |
| Jun 30, 2023 | -111,000.00 |
| Mar 31, 2023 | -1.19 Mn |
| Dec 31, 2022 | -1,000.00 |
| Sep 30, 2022 | -475,000.00 |
| Jun 30, 2022 | 49,000.00 |
| Mar 31, 2022 | 3,000.00 |
| Dec 31, 2021 | 204,000.00 |
| Sep 30, 2021 | -276,000.00 |